94 related articles for article (PubMed ID: 10851509)
1. Interleukin-2 in neuroblastoma: clinical perspectives based on biological studies.
Rueda F; Martí F; Pardo N; Badell I; Peiró M; Bertran E; Villén E; García J; Cubells J
Cancer Biother Radiopharm; 1996 Oct; 11(5):303-8. PubMed ID: 10851509
[TBL] [Abstract][Full Text] [Related]
2. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
[TBL] [Abstract][Full Text] [Related]
3. High-dose systemic interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: pilot study.
Pardo N; Martí F; Fraga G; Illa J; Badell I; Peiró M; Bertran E; García J; Rueda F; Cubells J
Med Pediatr Oncol; 1996 Dec; 27(6):534-9. PubMed ID: 8888813
[TBL] [Abstract][Full Text] [Related]
4. [Adoptive immunotherapy with interleukin 2 in oncology].
Favrot M; Bouffet E; Négrier S; Combaret V; Philip I; Philip T
Bull Cancer; 1990; 77(9):925-31. PubMed ID: 2224165
[TBL] [Abstract][Full Text] [Related]
5. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.
Higuchi CM; Thompson JA; Cox T; Lindgren CG; Buckner CD; Fefer A
Cancer Res; 1989 Oct; 49(20):5509-13. PubMed ID: 2477142
[TBL] [Abstract][Full Text] [Related]
6. Systemic interleukin-2 therapy in children with progressive neuroblastoma after high dose chemotherapy and bone marrow transplantation.
Favrot MC; Floret D; Negrier S; Cochat P; Bouffet E; Zhou DC; Franks CR; Bijman T; Brunat-Mentigny M; Philip I
Bone Marrow Transplant; 1989 Sep; 4(5):499-503. PubMed ID: 2790327
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-2 and lymphokine-activated killer cells in 15 children with advanced metastatic neuroblastoma.
Negrier S; Michon J; Floret D; Bouffet E; Gentet JC; Philip I; Cochat P; Stamm D; Costil J; Gaspard M
J Clin Oncol; 1991 Aug; 9(8):1363-70. PubMed ID: 1830096
[TBL] [Abstract][Full Text] [Related]
8. Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Preliminary results in children with acute lymphocytic leukemia and neuroblastoma.
Anderson PM; Bach FH; Ochoa AC
Cancer Immunol Immunother; 1988; 27(1):82-8. PubMed ID: 3260824
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication.
Foreman NK; Rill DR; Coustan-Smith E; Douglass EC; Brenner MK
Br J Cancer; 1993 May; 67(5):933-8. PubMed ID: 8494726
[TBL] [Abstract][Full Text] [Related]
10. Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.
Bosly A; Guillaume T; Brice P; Humblet Y; Staquet P; Doyen C; Chatelain B; Franks CR; Gisselbrecht C; Symann M
Exp Hematol; 1992 Sep; 20(8):962-8. PubMed ID: 1354620
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer.
Urba WJ; Steis RG; Longo DL; Kopp WC; Maluish AE; Marcon L; Nelson DL; Stevenson HC; Clark JW
Cancer Res; 1990 Jan; 50(1):185-92. PubMed ID: 2293554
[TBL] [Abstract][Full Text] [Related]
12. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.
Lauria F; Raspadori D; Ventura MA; Rondelli D; Zinzani PL; Gherlinzoni F; Miggiano MC; Fiacchini M; Rosti G; Rizzi S; Tura S
Bone Marrow Transplant; 1996 Jul; 18(1):79-85. PubMed ID: 8831999
[TBL] [Abstract][Full Text] [Related]
13. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.
Benyunes MC; Higuchi C; York A; Lindgren C; Thompson JA; Buckner CD; Fefer A
Bone Marrow Transplant; 1995 Aug; 16(2):283-8. PubMed ID: 7581149
[TBL] [Abstract][Full Text] [Related]
15. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies.
Higuchi CM; Thompson JA; Petersen FB; Buckner CD; Fefer A
Blood; 1991 Jun; 77(12):2561-8. PubMed ID: 2043762
[TBL] [Abstract][Full Text] [Related]
16. Distinct phenotypic and functional characteristics of human natural killer cells obtained by rapid interleukin 2-induced adherence to plastic.
Vujanovic NL; Rabinowich H; Lee YJ; Jost L; Herberman RB; Whiteside TL
Cell Immunol; 1993 Oct; 151(1):133-57. PubMed ID: 8402925
[TBL] [Abstract][Full Text] [Related]
17. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH
Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457
[TBL] [Abstract][Full Text] [Related]
18. A phase-II study of adoptive immunotherapy with continuous infusion of interleukin-2 in children with advanced neuroblastoma. A report on 11 cases.
Favrot M; Floret D; Michon J; Negrier S; Bouffet E; Coze C; Gaspard M; Cochat P; Thiesse P; Andreu G
Cancer Treat Rev; 1989 Jun; 16 Suppl A():129-42. PubMed ID: 2670209
[TBL] [Abstract][Full Text] [Related]
19. Autologous bone marrow transplantation followed by interleukin-2 in children with advanced leukemia: a pilot study.
Meloni G; Foà R; Tosti S; Vignetti M; Mancini F; Guarini A; Marchis D; Gavosto F; Mandelli F
Leukemia; 1992 Aug; 6(8):780-5. PubMed ID: 1640729
[TBL] [Abstract][Full Text] [Related]
20. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]